US 11,998,604 B2
Therapeutic uses for sodium thiosulfate formulations
Alexander Smith, Apex, NC (US)
Assigned to Fennec Pharmaceuticals Inc., Research Triangle Park, NC (US)
Filed by Fennec Pharmaceuticals Inc., Research Triangle Park, NC (US)
Filed on Nov. 22, 2022, as Appl. No. 17/992,703.
Application 17/992,703 is a continuation of application No. 17/849,477, filed on Jun. 24, 2022, granted, now 11,510,984.
Application 17/849,477 is a continuation of application No. 17/584,257, filed on Jan. 25, 2022, abandoned.
Application 17/584,257 is a continuation of application No. 17/005,997, filed on Aug. 28, 2020, granted, now 11,291,728, issued on Apr. 5, 2022.
Application 17/005,997 is a continuation of application No. 16/458,261, filed on Jul. 1, 2019, granted, now 10,792,363, issued on Oct. 6, 2020.
Claims priority of provisional application 62/693,502, filed on Jul. 3, 2018.
Claims priority of provisional application 62/693,503, filed on Jul. 3, 2018.
Prior Publication US 2023/0094842 A1, Mar. 30, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/20 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 33/04 (2006.01); A61K 33/243 (2019.01); A61K 47/02 (2006.01); A61K 47/18 (2017.01)
CPC A61K 47/20 (2013.01) [A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 33/04 (2013.01); A61K 33/243 (2019.01); A61K 47/02 (2013.01); A61K 47/18 (2013.01); A61K 47/183 (2013.01)] 26 Claims
 
1. A method of reducing ototoxicity in a human patient receiving a platinum based chemotherapeutic for the treatment of cancer sensitive to the platinum based chemotherapeutic comprising administering an effective amount of a pharmaceutical composition comprising aqueous anhydrous sodium thiosulfate, wherein the aqueous anhydrous sodium thiosulfate is at a concentration of about 0.5 M and further comprising about 0.004 M boric acid.